Hansa Biopharma AB (publ) (HNSBF)
USD 3.0
(0.0%)
USD 3.0
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 1.18 Billion SEK | 9.35% |
| 2022 | 1.08 Billion SEK | 324.9% |
| 2021 | 255.23 Million SEK | 32.68% |
| 2020 | 192.37 Million SEK | 89.68% |
| 2019 | 101.42 Million SEK | 19.4% |
| 2018 | 84.94 Million SEK | 70.73% |
| 2017 | 49.75 Million SEK | 84.42% |
| 2016 | 26.97 Million SEK | 114.77% |
| 2015 | 12.56 Million SEK | 178.72% |
| 2014 | 4.5 Million SEK | -11.57% |
| 2013 | 5.09 Million SEK | 99.38% |
| 2012 | 2.55 Million SEK | -58.7% |
| 2011 | 6.18 Million SEK | 9.82% |
| 2010 | 5.63 Million SEK | -57.39% |
| 2009 | 13.22 Million SEK | 220.05% |
| 2008 | 4.13 Million SEK | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 1.2 Billion SEK | 1.59% |
| 2024 Q2 | 1.24 Billion SEK | 3.6% |
| 2024 Q3 | 1.26 Billion SEK | 1.0% |
| 2023 Q4 | 1.18 Billion SEK | -3.84% |
| 2023 FY | 1.18 Billion SEK | 9.35% |
| 2023 Q1 | 1.08 Billion SEK | 0.05% |
| 2023 Q2 | 1.18 Billion SEK | 8.78% |
| 2023 Q3 | 1.23 Billion SEK | 4.48% |
| 2022 Q1 | 253.51 Million SEK | -0.67% |
| 2022 Q2 | 302.93 Million SEK | 19.49% |
| 2022 FY | 1.08 Billion SEK | 324.9% |
| 2022 Q3 | 1.03 Billion SEK | 242.05% |
| 2022 Q4 | 1.08 Billion SEK | 4.66% |
| 2021 Q2 | 187.05 Million SEK | 16.25% |
| 2021 Q1 | 160.9 Million SEK | -16.36% |
| 2021 FY | 255.23 Million SEK | 32.68% |
| 2021 Q3 | 192.7 Million SEK | 3.02% |
| 2021 Q4 | 255.23 Million SEK | 32.45% |
| 2020 Q1 | 65.54 Million SEK | -35.38% |
| 2020 Q4 | 192.37 Million SEK | 2.18% |
| 2020 Q3 | 188.26 Million SEK | 130.46% |
| 2020 Q2 | 81.69 Million SEK | 24.64% |
| 2020 FY | 192.37 Million SEK | 89.68% |
| 2019 Q3 | 67.24 Million SEK | 7.74% |
| 2019 Q1 | 62.95 Million SEK | -25.88% |
| 2019 Q2 | 62.41 Million SEK | -0.87% |
| 2019 FY | 101.42 Million SEK | 19.4% |
| 2019 Q4 | 101.42 Million SEK | 50.83% |
| 2018 Q4 | 84.94 Million SEK | 33.38% |
| 2018 Q2 | 60.92 Million SEK | 9.52% |
| 2018 Q1 | 55.62 Million SEK | 11.81% |
| 2018 FY | 84.94 Million SEK | 70.73% |
| 2018 Q3 | 63.68 Million SEK | 4.53% |
| 2017 Q3 | 27.02 Million SEK | -10.57% |
| 2017 Q2 | 30.22 Million SEK | 15.86% |
| 2017 Q1 | 26.08 Million SEK | -3.31% |
| 2017 FY | 49.75 Million SEK | 84.42% |
| 2017 Q4 | 49.75 Million SEK | 84.09% |
| 2016 Q3 | 19.96 Million SEK | -5.0% |
| 2016 Q4 | 26.97 Million SEK | 35.11% |
| 2016 FY | 26.97 Million SEK | 114.77% |
| 2016 Q2 | 21.01 Million SEK | 60.66% |
| 2016 Q1 | 13.08 Million SEK | 4.15% |
| 2015 Q1 | 15.04 Million SEK | 233.73% |
| 2015 Q2 | 12.6 Million SEK | -16.2% |
| 2015 Q4 | 12.56 Million SEK | 27.38% |
| 2015 Q3 | 9.86 Million SEK | -21.75% |
| 2015 FY | 12.56 Million SEK | 178.72% |
| 2014 Q4 | 4.5 Million SEK | 0.0% |
| 2014 Q1 | - SEK | -100.0% |
| 2014 FY | 4.5 Million SEK | -11.57% |
| 2014 Q2 | 4.86 Million SEK | 0.0% |
| 2013 Q4 | 5.09 Million SEK | -3.2% |
| 2013 FY | 5.09 Million SEK | 99.38% |
| 2013 Q2 | 2.91 Million SEK | 0.0% |
| 2013 Q3 | 5.26 Million SEK | 80.87% |
| 2012 Q2 | 2.25 Million SEK | 0.0% |
| 2012 Q4 | 2.55 Million SEK | 0.0% |
| 2012 FY | 2.55 Million SEK | -58.7% |
| 2011 Q4 | 6.18 Million SEK | 0.0% |
| 2011 FY | 6.18 Million SEK | 9.82% |
| 2011 Q2 | 4.44 Million SEK | 0.0% |
| 2010 Q2 | 3.37 Million SEK | 0.0% |
| 2010 Q4 | 5.63 Million SEK | 0.0% |
| 2010 FY | 5.63 Million SEK | -57.39% |
| 2009 FY | 13.22 Million SEK | 220.05% |
| 2009 Q4 | 13.22 Million SEK | 0.0% |
| 2009 Q2 | 4.71 Million SEK | 0.0% |
| 2008 FY | 4.13 Million SEK | 0.0% |
| 2008 Q4 | 4.13 Million SEK | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Capstone Therapeutics Corp. | 50.26 Million USD | -2259.376% |
| Skye Bioscience, Inc. | 14.07 Million USD | -8327.357% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | -1909.55% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -146527.819% |
| Qrons Inc. | 1.48 Million USD | -79560.552% |
| Adynxx, Inc. | - USD | -Infinity% |
| BioStem Technologies, Inc. | 15.9 Million USD | -7356.409% |
| CSL Limited | 18.62 Billion USD | 93.631% |
| Evofem Biosciences, Inc. | 72.47 Million USD | -1536.402% |
| Arch Therapeutics, Inc. | 9.46 Million USD | -12428.279% |
| Regen BioPharma, Inc. | 5.45 Million USD | -21629.579% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | -1482.911% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -2653195.597% |
| Rebus Holdings, Inc. | 5.24 Million USD | -22523.369% |
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -4322857.752% |
| Neon Bloom, Inc. | 1.22 Million USD | -96613.785% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -589568.152% |
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | -2124.776% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | -12276.48% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -281210.963% |
| SQZ Biotechnologies Company | 50.03 Million USD | -2269.985% |
| Intellipharmaceutics International Inc. | 12 Million USD | -9775.427% |
| Propanc Biopharma, Inc. | 3.85 Million USD | -30691.65% |
| Mesoblast Limited | 188.44 Million USD | -529.319% |
| Marizyme, Inc. | 26.67 Million USD | -4345.681% |
| Genus plc | 485 Million USD | -144.519% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | -20197.688% |
| Pharming Group N.V. | 244.07 Million USD | -385.886% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | -58897.03% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | -47028.872% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | -31108.342% |
| ContraFect Corporation | 32.53 Million USD | -3545.498% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | -59755.257% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | -30882.917% |
| IMV Inc. | 37.93 Million USD | -3026.363% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | -9968.75% |
| MultiCell Technologies, Inc. | 1617.67 USD | -73310093.055% |
| ONE Bio Corp. | 27.49 Million USD | -4213.083% |
| Accustem Sciences Inc. | 1.07 Million USD | -109784.558% |
| RVL Pharmaceuticals plc | 77.41 Million USD | -1431.856% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 2.11 Million USD | -55969.897% |
| Q BioMed Inc. | 8.13 Million USD | -14481.654% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | -1329.935% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | -22945.257% |
| Biomind Labs Inc. | 1.49 Million USD | -79034.359% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | -898.901% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | -13015.368% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | -6344.005% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -82607.947% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -834494.461% |
| Curative Biotechnology, Inc. | 5.74 Million USD | -20539.644% |
| GB Sciences, Inc. | 5.41 Million USD | -21790.254% |
| Alpha Cognition Inc. | 7.16 Million USD | -16452.05% |
| HST Global, Inc. | 593.59 Thousand USD | -199686.217% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -94080.717% |
| Halberd Corporation | 728.71 Thousand USD | -162639.959% |
| Enzolytics Inc. | 365.26 Million USD | -224.669% |
| Agentix Corp. | 2.51 Million USD | -47137.244% |
| Resverlogix Corp. | 67.39 Million USD | -1659.625% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -141294.033% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 444.95 Million USD | -166.528% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | -69090.023% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | -4692.353% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | -9863.093% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | -32256.451% |
| AVAX Technologies, Inc. | 3.99 Million USD | -29594.36% |
| Zenith Capital Corp. | 27.56 Thousand USD | -4301532.268% |
| Genscript Biotech Corporation | 1.32 Billion USD | 10.556% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -496818.971% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | -31657.36% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -174085.925% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | -43634.292% |
| Kadimastem Ltd | 3.5 Million USD | -33736.291% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -1771803.061% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -255101.109% |
| LadRx Corporation | 2.2 Million USD | -53792.384% |
| Cell Source, Inc. | 15.8 Million USD | -7402.616% |
| Regen BioPharma, Inc. | 5.45 Million USD | -21629.579% |
| NovAccess Global Inc. | 7.86 Million USD | -14986.598% |
| Affymax, Inc. | 8.87 Million USD | -13268.47% |
| Itoco Inc. | 1.65 Million USD | -71636.762% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | -57705.48% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | -19505.174% |
| Mobile Lads Corp. | 1.31 Million USD | -90186.997% |
| CytoDyn Inc. | 127.89 Million USD | -827.266% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -2837089.885% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | -75610.828% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | -10636.858% |
| SYBLEU INC | 681.41 Thousand USD | -173937.918% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | -19335.193% |
| International Stem Cell Corporation | 5.27 Million USD | -22373.318% |
| Bioxytran, Inc. | 3.24 Million USD | -36395.369% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -189401.429% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | -25585.183% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | -2792.763% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | -5226.373% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | -58452.612% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | -21548.722% |
| Neutra Corp. | 973.52 Thousand USD | -121716.299% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | -3987.255% |
| PureTech Health plc | 125.58 Million USD | -844.329% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | -31464.481% |
| IXICO plc | 1.9 Million USD | -62307.093% |
| IntelGenx Technologies Corp. | 20.52 Million USD | -5676.789% |
| Gelesis Holdings, Inc. | 103.32 Million USD | -1047.765% |
| CSL Limited | 18.62 Billion USD | 93.631% |
| Cellectis S.A. | 249.36 Million USD | -375.566% |